

# ForPatients

by Roche

Non Hodgkin Lymphoma (NHL)

## A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

**Trial Status**  
Recruiting

**Trial Runs In**  
2 Countries

**Trial Identifier**  
NCT05207670 ML43389

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma [NHL]).

**Genentech, Inc.**  
Sponsor

**Phase 2**  
Phase

---

**NCT05207670 ML43389**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---